Navigation Links
Daiichi Sankyo's Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial
Date:11/19/2013

ar mortality rates versus warfarin: the incidence was 3.17% for warfarin, 2.74% (p=0.013) for the edoxaban 60 mg treatment arm and 2.71% (p=0.008) for the edoxaban 30 mg treatment arm. The primary net clinical outcome (defined in the study protocol as the composite of death, stroke, SEE or major bleeding) was 8.11% per year for warfarin, 7.26% per year for the edoxaban 60 mg treatment arm (p=0.003) and 6.79% per year for the edoxaban 30 mg treatment arm (p<0.001).2

About ENGAGE AF-TIMI 48

ENGAGE AF-TIMI 48 (Effective aNticoaGulation with Factor XA next GEneration in Atrial Fibrillation) was a three-arm, randomized, double-blind, double-dummy, global phase 3 clinical trial comparing once-daily edoxaban with warfarin in 21,105 patients with NVAF at moderate-to-high risk of thromboembolic events at 1,393 centers in 46 countries.2

Patients were randomized (1:1:1) to receive warfarin (n=7,036), edoxaban 60 mg (n=7,035) or edoxaban 30 mg (n=7,034). Edoxaban dosage was reduced by half if any of the following was present at randomization or during the course of the study: creatinine clearance 30-50 mL/min, body-weight < or = 60 kg, or concomitant verapamil, quinidine or dronedarone (standard dosing was resumed if the concomitant drug was discontinued and no other dose reduction factors were present). The primary efficacy outcome was the time to first adjudicated stroke or SEE. The principal safety outcome was adjudicated major bleeding. Complete information on the primary endpoint was ascertained for 99.5% of the total 56,346 patient-years of potential follow-up, with only one patient lost to follow-up. Warfarin therapy was proactively monitored throughout the trial, resulting in a median time within therapeutic range (TTR) of 68.4%. Adverse event (excluding bleeding) and discontinuation rates were similar among the three treatment groups.2

ENGAGE AF-TIMI 48 implemented a unique, pre-specified plan to trans
'/>"/>

SOURCE Daiichi Sankyo
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
2. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
3. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
4. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
5. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
6. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
7. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
8. Sosei Group Corporation: QVA149 Filed by Licensing Partner as a Once-Daily Maintenance Treatment for COPD in Japan
9. Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe
10. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
11. Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 25, 2014   Heska Corporation (NASDAQ: ... a provider of advanced veterinary diagnostic and other specialty ... Executive Chair, will attend The Benchmark Company, LLC,s Micro Cap ... will be held at The Palmer House Hilton, 17 E. ... a.m. to 2:30 p.m. Please email hska@haydenir.com or ...
(Date:11/26/2014)... BOCA RATON, Fla. , Nov. 25, 2014 ... has entered into a multi-product ANDA agreement with ... Maryland ) under which Breckenridge and Pii ...  Under the terms of the agreement, Pii will ... will market and distribute the products under its ...
(Date:11/26/2014)... and HERZLIYA PITUACH, Israel, Nov. 25, 2014 ... or "the Company"), a clinical stage biopharmaceutical company ... targeted therapeutics for the treatment of inflammatory diseases ... previously announced underwritten public offering of 3,450,000 units, ... the Company,s common stock, par value $0.0001 per ...
Breaking Medicine Technology:Heska to Attend Benchmark Micro Cap Discovery Conference 2Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with Pharmaceutics International, Inc. 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5
... ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX ) ... 31, 2011. "We are pleased to have completed ... the FDA this year to reach agreement on the protocol ... treatment of sickle cell crisis," said Brian M. Culley, Chief ...
... CYPRESS, Calif., May 9, 2011 Medison and Samsung ... Medison. The combined company, a joint partnership between Korea,s ... world,s largest and most technologically-advanced electronics and consumer goods ... into a global leader in medical device industry. ...
Cached Medicine Technology:ADVENTRX Reports First Quarter 2011 Financial Results 2ADVENTRX Reports First Quarter 2011 Financial Results 3ADVENTRX Reports First Quarter 2011 Financial Results 4ADVENTRX Reports First Quarter 2011 Financial Results 5Samsung Medison Pledges to Become a World-Class Medical Device Company 2
(Date:11/27/2014)... Petersburg, Fl (PRWEB) November 28, 2014 Let ... , Beautiful Christmas boxes with bows on top, filled with ... All prices are deeply discounted today while quantities last - ... . , All products are also available on Amazon at ... found on each Sublime shop product page for ease. , ...
(Date:11/27/2014)... England (PRWEB) November 27, 2014 Cambrionix Ltd ... Deloitte Technology Fast 50, a ranking of the 50 fastest-growing ... percentage revenue growth over the last five years. Cambrionix ... Cambrionix Ltd ranked first in the region of Cambridgeshire and ... O’Hara, Managing Director Says:, “This award is recognition of the ...
(Date:11/27/2014)... "As a nurse I see patients every day ... said an inventor from Whiting, N.J. "I put my ... prevent leakage and keep them dry and comfortable." , ... prevents stains on pants, skirts and bottoms, which saves ... the individual has time to get to the bathroom. ...
(Date:11/27/2014)... Thompson HealthDay Reporter WEDNESDAY, ... appears to be safe and produces an immune system response ... early clinical trial results reported by the U.S. National Institutes ... trial for the vaccine paves the way for field-testing it ... Leone as early as January, said Dr. Anthony Fauci, director ...
(Date:11/27/2014)... Indian Trail, NC (PRWEB) November 27, 2014 ... for over 12 years in the Charlotte area ... and fraud examination services to businesses of varying ... with local business owners to meet all of ... received QuickBooks certification through the QuickBooks ProAdvisor Program. ...
Breaking Medicine News(10 mins):Health News:Big Christmas Sales Begin Today at Sublime Beauty® for all Christmas Gift Selections and Skincare Sets 2Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 2Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 3Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 4Health News:Early Trial Promising for Ebola Vaccine 2Health News:Early Trial Promising for Ebola Vaccine 3Health News:Jeffrey Carlini becomes Intuit Proadvisor and receives QuickBooks certification 2
... BERKELEY, CA An $18 million, three-year grant to ... cancer was awarded today to a multi-institutional "Dream Team" ... Gray, a renowned cancer researcher with the U.S. Department ... was awarded by Stand Up To Cancer, an Entertainment ...
... Virtual Event for Research Scientists, Engineers and Professionals Slated for ... Abstracts(at)BioConferenceLive.com , ... Boston, MA (PRWEB) ... media company that produces online events for the healthcare, education ...
... of Insomnia and Potential Solutions NEW YORK, May 27 ... Center for Medicine in the Public Interest (CMPI), has ... and treatment of insomnia translates to billions of dollars ... CMPI also estimates insomnia is responsible for at ...
... suggests what to include in a Pet Evacuation KitSAN ANTONIO, ... 1 and is expected to bring 12 named storms, with ... pets to evacuate or take shelter against these devastating storms ... www.purinacare.com ) suggests preparing a Pet Evacuation ...
... Effectiveness of Managing Data Systems Delivery [While Providing ... SunGard Availability Services has partnered with Phoenix ... outsourcing, consulting and revenue cycle management solutions, to ... records (EMR) and other technologies essential to quality ...
... ban on direct-to-consumer drug advertising and has exposed Canadians ... those for drugs with life-threatening risks, according to a ... and James M. Wright from UBC,s Centre for Health ... drugs from 1995 to 2006 and saw spending rise ...
Cached Medicine News:Health News:Berkeley Lab scientist co-leads breast cancer 'dream team' 2Health News:Berkeley Lab scientist co-leads breast cancer 'dream team' 3Health News:PlatformQ and LabRoots Announce BioConference Live, Online Conference for the Life Science Research and Laboratory Sciences Community 2Health News:PlatformQ and LabRoots Announce BioConference Live, Online Conference for the Life Science Research and Laboratory Sciences Community 3Health News:Ignoring Insomnia Costs America $42 Billion a Year 2Health News:Ignoring Insomnia Costs America $42 Billion a Year 3Health News:Keep Your Pets Safe in a Hurricane 2Health News:SunGard Availability Services and Phoenix Health Systems Join Forces to Deliver Complete Software Application and Infrastructure Management to Community Hospitals 2Health News:SunGard Availability Services and Phoenix Health Systems Join Forces to Deliver Complete Software Application and Infrastructure Management to Community Hospitals 3Health News:SunGard Availability Services and Phoenix Health Systems Join Forces to Deliver Complete Software Application and Infrastructure Management to Community Hospitals 4Health News:Legal loophole exposes Canadians to drug advertising banned in US: UBC research 2